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OBJECTIVE—Recently, several drugs have been shown to
exert beneﬁcial effects for metabolic syndrome through mild
regulation of mitochondrial function. Hence, we explored a
strategy of targeting mitochondrial function to improve glucose
and lipid metabolism.
RESEARCH DESIGN AND METHODS—Mitochondrial mem-
brane potential (m) is a marker of mitochondrial function;
therefore, we set up a high-throughput screening assay of mi n
L6 myotubes. The effects of a selected lead compound were
investigated in vitro and in vivo in relation to metabolic syndrome.
RESULTS—A novel small-molecule compound, C1, was identi-
ﬁed through this high-throughput screening. C1 depolarized m
in L6 myotubes without cytotoxicity and led to increased cellular
AMP-to-ATP ratio, activation of AMP-activated protein kinase
(AMPK), and enhanced glucose uptake. It also stimulated the
AMPK pathway in HepG2 cells, leading to decreased lipid con-
tent. Intriguingly, C1 inhibited respiration in L6 myotubes but did
not affect respiration in isolated muscle mitochondria, suggesting
that it may depolarize m indirectly by affecting the supply of
electron donors. Acute administration of C1 in C57BL/6J mice
markedly increased fat oxidation and the phosphorylation of
AMPK and acetyl-CoA carboxylase in the liver. In diabetic db/db
mice, chronic administration of C1 signiﬁcantly reduced hyper-
glycemia, plasma fatty acids, glucose intolerance, and the mRNA
levels of phosphoenolpyruvate carboxykinase and glucose-6-
phosphatase in the liver.
CONCLUSIONS—Our results demonstrate a novel small mole-
cule that mildly depolarizes m and is able to improve glucose
and lipid metabolism to exert beneﬁcial effects for metabolic
syndrome. These ﬁndings suggest that compounds regulating
mitochondrial function may have therapeutic potential for type 2
diabetes. Diabetes 59:256–265, 2010
C
urrent medications for type 2 diabetes are insuf-
ﬁcient, and, as such, new antidiabetic agents
that ameliorate insulin resistance and hyperlip-
idemia are needed to combat this disease. AMP-
activated protein kinase (AMPK) serves as a “fuel gauge”
in cells and represents an attractive target for treating
metabolic disease (1,2). AMPK is activated under condi-
tions that signify cellular stress, such as exercise, isch-
emia, and hypoxia, which induce an increment in the
intracellular AMP-to-ATP ratio (3). Once activated, it or-
chestrates a variety of metabolic processes including
stimulation of glucose uptake in muscle, increases in fatty
acid oxidation, and inhibition of hepatic cholesterol and
triglyceride synthesis and lipogenesis (4,5). These meta-
bolic responses are primarily mediated through phosphor-
ylation of enzymes or transcription factors and co-
activators that regulate gene expression (3).
Interestingly, AMPK can also be activated by the antidi-
abetic drugs metformin and thiazolidinediones (TZDs)
(6,7) and other natural products with antiobesity and
antidiabetes properties, such as berberine (8) and res-
veratrol (9). The mechanism by which these agents
exert their beneﬁcial metabolic effects has been shown
to be, at least in part, via modulating mitochondrial
function (10–14). These ﬁndings raised the possibility of
discovering novel therapeutics for metabolic disease
from compounds that perturb mitochondrial function
and thus activate AMPK.
In this study, we set up a high-throughput screening
assay based on mitochondrial membrane potential (m)
and identiﬁed a small-molecule compound C1 that depo-
larizes m in a mild manner without causing cell toxicity.
C1 increases cellular AMP-to-ATP ratio and activates
AMPK, resulting in beneﬁcial metabolic effects in L6
myotubes and HepG2 cells and in db/db mice. Interest-
ingly, our studies indicate that C1 causes mild inhibition of
mitochondrial respiration through a mechanism distinct
from TZDs, metformin, or berberine (13). These ﬁndings
suggest that targeted identiﬁcation of mild mitochondrial
modulators may represent an effective approach for the
discovery of new therapeutics for type 2 diabetes.
RESEARCH DESIGN AND METHODS
Materials. Compound C, 5-aminoimidazole-4-carboxamide-1-D-ribofurano-
side (AICAR), 5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-imidacarbocyanine
iodide (JC-1), carbonyl cyanide m-chlorophenylhydrazone (CCCP), wortman-
nin, metformin, rosiglitazone, troglitazone, and insulin were obtained from
Sigma Aldrich (St. Louis, MO). Radiochemical 2-deoxy-[
3H]-D-glucose and
Western blotting detection kits (enhanced chemiluminescence) and Hyperﬁlm
were purchased from Amersham Biosciences (Uppsala, Sweden).
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medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 4.5
g/l glucose, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in 5%
CO2. For L6 myoblast differentiation, the concentration of FBS was decreased
from 10 to 2%. Myotubes were used for experiments 5–7 days after differen-
tiation. HepG2 cells were maintained in DMEM containing 10% FBS, 1 g/l
glucose, 100 units/ml penicillin, and 100 g/ml streptomycin at 37°C in 5% CO2.
Mitochondrial membrane potential assay. This assay was based on a
previous report with modiﬁcations (15). Brieﬂy, 7,000 L6 myoblasts per well
were seeded into black 96-well optical-bottom plates (Greiner Bio-One,
Dusseldorf, Germany) at 100 l per well. On day 5 of differentiation,
compounds were added and plates were incubated at 37°C for 10 min. After
incubation, 100 l fresh medium containing 0.2 g JC-1 was added to each
well. Plates were incubated for another 20 min at 37°C, and each well was
washed three times with 100 l Krebs-Ringer phosphate HEPES buffer.
Fluorescence was measured in a Flexstation II plate reader (Molecular
Device, Union City, CA) with ﬁrst at lengths of excitation and emission
(ex/em) 530 nm/580 nm (“red”) and then at ex/em 485 nm/530 nm (“green”).
The ratio of red to green reﬂects the m. The coefﬁcient of variation (CV%)
and Z factor for the quality control of high-throughput screening assay were
estimated (16).
Adenine nucleotide extraction and measurement. L6 myotubes cultured
in 60-mm dishes treated with C1 were washed with PBS (140 mmol/l NaCl, 2.7
mmol/l KCl, 10 mmol/l Na2HPO4, 1.8 mmol/l KH2PO4) and trypsinized. The
samples for cellular adenine nucleotides measurement were prepared and
analyzed as previously described (17).
Measurement of 2-deoxy-[
3H]-D-glucose uptake. 2-Deoxyglucose uptake
was measured as described (17,18). Brieﬂy, after stimulation with C1 or
insulin, cells were washed three times with HEPES-buffered saline solution
(20 mmol/l HEPES [pH 7.4], 136 mmol/l NaCl, 4.7 mmol/l KCl, 1.25 mmol/l
MgSO4, 1.2 mmol/l CaCl2) followed by incubation with 2-deoxy-[
3H]-D-glucose
for 10 min. Cells were washed with ice-cold PBS, lysed using 0.1% Triton-X
100, and radioactivity counted.
Western blot analysis. Cell lysates were subjected to electrophoresis
through 8% SDS-PAGE and blotted with antibodies for AMPK, phospho-AMPK,
acetyl-CoA carboxylase (ACC), phospho-ACC, Akt, and phospho-Akt pur-
chased from Cell Signaling Technology (Beverly, MA) and -actin from
Upstate (Billerica, MA). The immunoblots were visualized by chemilumines-
cence using the enhanced chemiluminescence Western Blotting System.
Determination of triglyceride and cholesterol contents. HepG2 cells
cultured in 60-mm dishes were lysed in RIPA buffer (20 mmol/l Tris-HCl, pH
8.0, 1% Nonidet P-40, 1 mmol/l sodium orthovanadate, 1 mmol/l phenylmeth-
ylsulfonylﬂuoride, 1 mmol/l dithiothreitol, 1 mmol/l EDTA, 1 mmol/l EGTA, 2
g/ml aprotinin, 2 g/ml leupeptin, and 1 g/ml pepstatin). Triglyceride and
total cholesterol contents were determined in cell lysates using a colorimetric
assay and are expressed as milligram lipid per milligram of cellular protein as
described (19,20).
Measurement of respiration in L6 myotubes and isolated mitochondria.
Mitochondria were isolated from mouse quadriceps muscle using a method
previously described (13). Respiration measurements in L6 myotubes and
isolated mitochondria were conducted at 37°C in a Clark type oxygen
electrode (Strathkelvin Instruments, Motherwell, Scotland). For L6 myotubes,
respiration measurements were conducted using cell culture medium, while
for mitochondria, a standard respiration medium was used (13). Cells or
mitochondria were transferred to the electrode chamber, and after attaining a
steady rate of oxygen consumption, C1 was added dose-dependently, and its
effect on oxygen consumption was recorded.
Determination of lactate content. The cells were cultured in a 24-well plate
and treated with C1 and positive control in serum-free cell culture medium for
the indicated time. Lactate in the medium was measured with a lactate assay
kit from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).
Animal experiments. All animal experiments were approved by the Animal
Ethics Committee of either the Shanghai Institute of Materia Medica or
Garvan Institute of Medical Research/St. Vincent’s Hospital, where the exper-
iments were conducted. Male C57BL/6J db/db and lean C57BL/6J mice were
housed in a temperature-controlled room (22  2°C), with a light/dark cycle
of 12 h. At 8–14 weeks of age, mice were randomly assigned to acute or
chronic treatment. The acute effects of C1 (50 mg/kg) on oxygen consumption
rate (VO2) and respiratory exchange ratio were measured using an eight-
chamber indirect calorimeter (Oxymax series; Columbus Instruments, Colum-
bus, OH) as described previously (21). To examine the acute effects of C1 on
activation of AMPK, lean mice were given intraperitoneal injections of vehicle
(0.9% NaCl), C1 (20 mg/kg), or AICAR (400 mg/kg) as a positive control.
Animals were killed after 2 h with the liver freeze clamped for the determi-
nation of phosphorylation of AMPK and ACC. For chronic treatment, lean and
db/db mice received oral administration of either vehicle (0.5% methylcellu-
lose) or C1 (50 mg  kg
1  day
1) or metformin (250 mg  kg
1  day
1) for 4
weeks. Body weight and food intake were recorded daily. Fasting and
random-fed blood glucose levels were measured every other week. Glucose
tolerance test (2 g/kg glucose i.p.) was performed in overnight-fasted mice
as described before (13). Plasma concentrations of nonesteriﬁed fatty acids
(NEFAs) and triglyceride were measured using kits from Wako Diagnostics
(Richmond, VA) and Nanjing Jiancheng Bioengineering Institute (Nanjing,
China), respectively. Plasma insulin content was measured by using a rodent
insulin enzyme-linked immunosorbent assay (ELISA) kit (Linco Research, St.
Charles, MO). After 4 weeks of treatment, animals were killed with the liver
freeze clamped for the determination of gene expression.
RNA isolation and real-time PCR. Gene expression was analyzed by
real-time PCR (RT-PCR). Total RNA prepared from mouse livers was ex-
tracted with Trizol (Invitrogen). Complementary DNA generated by M-MLV
Reverse Transcriptase (Promega, Madison, WI) was analyzed by quantitative
PCR using an SYBR Premix Ex Taq (TaKaRa, Dalian, China). All samples were
run in duplex with and normalized to tubulin expression. The sequences of
oligonucleotide primers used are described elsewhere (22).
Glucose output assay. Primary hepatocytes were prepared from Sprague-
Dawley rats as previously described (23,24) and were plated with DMEM
containing 1 g/l glucose (Invitrogen) in 12-well plates (5  10
5 cells in each
well). After 4-h attachment, cells were changed to serum-free medium and
incubated with 5, 10, and 20 mol/l C1 for 16 h. The medium was then replaced
with 500 l glucose production buffer consisting of glucose-free DMEM,
without phenol red, supplemented with 20 mmol/l sodium lactate and 2
mmol/l sodium pyruvate. After a 4.5-h incubation, 50 l medium was collected
and the glucose concentration was measured with a colorimetric glucose
assay kit (Fudan-Zhangjiang, Shanghai, China).
Statistical analysis. Results are presented as means  SE. Differences
between groups were analyzed by Student’s t test. For respiration measure-
ments, the effect of C1 treatment is given as a percentage of intraindividual
control values (100%), with P values calculated by paired t tests. P 	 0.05 was
regarded as statistically signiﬁcant.
RESULTS
Identiﬁcation of C1 by m and AMPK assays in L6
myotubes. m provides an index of mitochondrial func-
tion, and therefore to screen for novel compounds that can
affect mitochondrial function, we developed a high-
throughput screening assay in a 96-well format for mi n
L6 myotubes using JC-1, a positively charged ﬂuorescent
compound. Initially, we characterized this assay using the
mitochondrial uncoupler CCCP as a control and observed
a dose-dependent decrease in m with CCCP (Fig. 1A).
The CV% and Z factor determined with CCCP were 8.5
and 0.6, respectively, which meet the criteria for quality
control of a high-throughput screening assay.
Next, the effect of berberine, TZDs, and metformin on
m was examined, since we have previously reported
that these agents exert their beneﬁcial effects, in part, by
perturbing mitochondrial function (13). A decrease in
mo f
20% was observed when L6 myotubes were
treated with the above compounds for 30 min (Fig. 1B).
We also tested the AMPK activator AICAR (25,26) and
observed no effect on m. A recent study reported that
AICAR (0.5 mmol/l) inhibits oxidative phosphorylation in
primary mouse hepatocytes (27), and thus it would be
expected to also decrease m. However, there is clearly
a difference in sensitivity between cell types, as we have
found that even at a concentration of 2 mmol/l, AICAR
does not inhibit respiration in L6 myotubes (data not
shown).
We then proceeded to randomly screen our compound
library, which contains pure synthetic compounds and
natural products collected from different sources, and
from this screen, we identiﬁed a small molecule (449.14
Da), named C1 (Fig. 1C), as a compound able to depolarize
m in a dose-dependent manner within a 30-min treat-
ment. Compared with CCCP (Fig. 1D), which depolarized
m within a narrow dose range, C1 depolarized mi n
a relatively mild manner, reaching 	50% even at the
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experiments, a concentration of 20 mol/l was used, since
this dose gave a decrease in the m( 
20%) similar to the
other antidiabetic agents tested (Fig. 1B).
Because AMPK acts as an energy sensor, we examined
if treatment of L6 myotubes with C1 would lead to
activation of AMPK. We observed a dose- and time-
dependent activation of AMPK by C1 as evidenced by the
increase in Thr-172 phosphorylation of the -catalytic
subunit of AMPK and the increase in Ser-79 phosphoryla-
tion of its downstream target ACC (Fig. 1E and F).
C1 stimulates glucose uptake via the AMPK pathway
in L6 myotubes. Several studies have linked AMPK
activation with the stimulation of glucose uptake and
utilization by skeletal muscle (28,29). As shown in Fig. 2A,
C1 stimulated glucose uptake dose-dependently, with 20
mol/l C1 resulting in a nearly twofold increase compared
with controls. To further elucidate the mechanism of
C1-stimulated glucose uptake, we measured the effects of
100 nmol/l insulin and 20 mol/l C1, respectively, or
together on glucose uptake. As shown in Fig. 2B, when L6
myotubes were treated with insulin and C1 together,
glucose uptake was stimulated to a higher extent com-
pared with single treatment with insulin or C1. This
additive effect indicated that C1 stimulated glucose
uptake in L6 myotubes through a pathway distinct from
the insulin-signaling pathway. Indeed, while the phos-
phatidylinositol 3 kinase inhibitor wortmannin was
able to block glucose uptake and Ser-473 phosphoryla-
tion of Akt by insulin, C1 did not activate Akt and
wortmannin did not inhibit the stimulation of glucose
uptake by C1 (Fig. 2C and D). We next examined
whether the effects of C1 were dependent on AMPK by
using the AMPK inhibitor compound C. Compound C
pretreatment abolished the ability of C1 to increase
glucose uptake (Fig. 2C) and blocked the phosphoryla-
tion of AMPK and ACC by C1 (Fig. 2D).
C1 decreases lipid contents via the AMPK pathway in
HepG2 cells. To investigate whether C1 also inﬂuences
lipid metabolism, we tested its effects in human hepatoma
HepG2 cells. As shown in Fig. 3A, C1 decreased the
contents of triglyceride and cholesterol dose-dependently,
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FIG. 1. High-throughput screening for mild inhibitors of m and AMPK assays in L6 myotubes. For the m assay, L6 myotubes in a 96-well plate
were treated with indicated agents for 10 min and then incubated with 1 g/ml JC-1 for another 20 min. Cells were washed with Krebs-Ringer
phosphate HEPES buffer three times and then used for ﬂuorescence intensity measurement. A: Detection of CCCP induced m depolarization
in a JC-1–based ﬂuorescent high-throughput assay in L6 myotubes. CCCP depolarizes m in a dose-dependent manner. B: Effect of known
antidiabetic agents on m in L6 myotubes. Berberine (5 mol/l), troglitazone (5 g/ml), rosiglitazone (10 g/ml), metformin (2 mmol/l), and
AICAR (2 mmol/l) on m. C: Chemical structure of compound C1. D: Dose-dependent depolarization of mb yC 1 .E and F: Effects of C1 on
the AMPK signaling pathway by Western blots. For the dose-dependent assays, C1 was incubated with L6 myotubes for 60 min and for the time
course measurement 20 mol/l C1 was used. Total cell lysates were prepared from L6 myotubes, resolved by 8% SDS-PAGE and immunoblotted
with speciﬁc antibodies as indicated. Results are presented as percentage of vehicle (DMSO) control group. **P < 0.01 compared with DMSO
group (n  3 independent experiments).
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potency to that of 2 mmol/l metformin. Similar to the L6
myotubes, C1 dose-dependently activated the AMPK path-
way in HepG2 cells, as evidenced by the increase in AMPK
and ACC phosphorylation (Fig. 3B). The effects of C1 and
metformin on ACC phosphorylation and decreasing tri-
glyceride content could be partially blocked by compound
C pretreatment (Fig. 3C and D), suggesting that, like
metformin (19), the lipid-lowering effect of C1 is largely
mediated through AMPK.
C1 inﬂuences mitochondrial metabolism via a mech-
anism different from TZDs and metformin. ATP gen-
eration occurs primarily in mitochondria, and a decrease
in m will lead to a reduced ATP production, an increase
in the AMP-to-ATP ratio, and activation of AMPK (30,31).
Because the activation of AMPK by TZDs and metformin
involves inhibition of respiratory complex I, we wondered
if C1 shares a similar mechanism. C1 treatment for 1 h
increased the AMP-to-ATP ratio in a dose-dependent man-
ner, up to fourfold greater than basal levels at a concen-
tration of 40 mol/l (Fig. 4A). We also observed a time-
dependent increase in the AMP-to-ATP ratio with 20
mol/l C1 (Fig. 4B). To determine if the change in nucle-
otide ratio was due to an effect on cellular respiration, we
examined oxygen consumption in L6 myotubes and ob-
served a dose-dependent inhibition of respiration at simi-
lar concentrations of C1 (Fig. 4C). To determine if this
effect was due to a speciﬁc inhibition of mitochondrial
function, we isolated muscle mitochondria and examined
the effect of C1 on ADP-stimulated respiration in the
presence of complex I (glutamate) or complex II (succi-
nate) substrates. Surprisingly, C1 did not inhibit mitochon-
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FIG. 2. Effect of C1 on glucose uptake in relation to the AMPK and phosphatidylinositol 3-kinase/Akt signaling pathways. A: Dose-dependent
effects of C1 on glucose uptake. L6 myotubes were treated for 1 h with a different dose of C1 as described in RESEARCH DESIGN AND METHODS. B:
Additive effect of C1 on insulin-stimulated glucose uptake. Cells were treated with 100 nmol/l insulin and 20 mol/l C1 for 30 min and 1 h,
respectively. C: Inﬂuences of wortmannin and compound C on C1-induced glucose uptake. After serum deprivation for 2 h, 25 nmol/l wortmannin
or 20 mol/l compound C was added to the cells for 30 min before and during the incubation with 20 mol/l C1 for 1 h. A total of 100 nmol/l insulin
was added in the last 30 min. D: The effects of C1 on AMPK, ACC, and Akt phosphorylation. **P < 0.01 compared with DMSO group; §P < 0.05.
n  3 independent experiments.
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had no effect on mitochondrial respiration in the absence
of ADP (data not shown).
Because a decrease in aerobic respiration may lead to
an elevation in anaerobic respiration to compensate, we
tested whether C1 increased lactate release, a marker of
anaerobic respiration. C1 (20 mol/l) acutely increased
lactate production from L6 myotubes by 20 and 65% at 1
and 4 h, respectively (Fig. 4E). A similar effect was
observed for cells treated with 50 mol/l troglitazone. In
HepG2 cells, both C1 and metformin also increased lactate
release within 1–4 h (Fig. 4F).
Acute effects of C1 in mice. Based on the in vitro data,
we examined whether C1 could acutely affect whole-body
metabolism in C57BL/6J lean mice. Animals were dosed
with 50 mg/kg C1 and in the 6 h following, we observed no
change in VO2 (data not shown), but a signiﬁcant decrease
in respiratory exchange ratio, indicating a shift to fatty
acid utilization (Fig. 5A and B). To investigate if AMPK
might be involved, we measured the phosphorylation of
AMPK and ACC in the liver, 2 h after C1 treatment, and
observed a clear activation of this pathway (Fig. 5C), to a
degree similar to that of the positive control AICAR (Fig.
5D and E) (21).
Chronic effects of C1 in mice. To assess the antidiabetic
potential of C1 in vivo, db/db mice and lean mice were
administered 50 mg  kg
1  day
1 for 4 weeks. We
compared the efﬁcacy of C1 with the well-known antidia-
betic agent metformin (250 mg  kg
1  day
1). Food intake
and body weight gain were checked daily, and no signiﬁ-
cant differences were observed between the three groups
(Table 1). In lean mice, plasma parameters were generally
unchanged by C1 and metformin treatment, apart from a
small increase (12%) in random-fed glucose levels in
C1-treated animals. In db/db mice, random-fed and fasting
blood glucose levels were decreased 42 and 21%, respec-
tively, by C1 treatment, while metformin decreased blood
glucose levels by 
20% (Table 1). Plasma levels of insulin
and triglyceride were unchanged by C1 or metformin
treatment, but NEFA levels were decreased by 
20% in
C1-treated db/db mice. C1 and metformin did not alter
glucose tolerance in lean mice (Fig. 6A and B); however, in
db/db mice, both agents improved glucose clearance, as
evidence by the 
25% decrease in the AUC (Fig. 6C and
D). Liver gluconeogenesis plays an important role in
regulating glucose levels; therefore, we assessed the expres-
sion of two key gluconeogenic enzymes, glucose-6-phospha-
tase (G6Pase) and phosphoenolpyruvate carboxykinase
(PEPCK), in response to C1 treatment. The expression of
G6Pase and PEPCK was approximately threefold higher in
db/db mice compared with lean controls (Fig. 6E and F).
C1 treatment reduced the expression of G6Pase and
PEPCK by 45 and 62%, respectively, in db/db mice. Inter-
estingly, in lean mice, C1 treatment did not affect PEPCK
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G6Pase. To more directly examine the effect of C1 on
gluconeogenesis, we measured glucose output in primary
hepatocytes. As shown in Fig. 6G, overnight treatment of
hepatocytes with C1 dose-dependently inhibited glucose
output by 25–35%.
DISCUSSION
Interest in mitochondrial biology has undergone a resur-
gence in recent years, with the discovery that mitochon-
drial dysfunction is linked with several diseases, including
obesity and type 2 diabetes (32). Intriguingly, mild pertur-
bation of mitochondrial function has been associated with
beneﬁcial effects for obesity and type 2 diabetes (10–
14,28,33). Metformin and TZDs, drugs widely prescribed
for the treatment of type 2 diabetes, exert their antidia-
betic effects partly through inhibition of respiratory com-
plex I (10–12). We have recently shown that berberine, a
natural product with antidiabetic effects, also inhibits
complex I of the respiratory chain (13). A common ﬁnding
of these reports is that inhibition of mitochondrial func-
tion leads to activation of AMPK in tissues such as muscle
and liver, and the pleitropic actions of AMPK likely
mediate most of the beneﬁcial effects of these compounds.
Therefore, we hypothesized that small molecules, which
depolarize m, would activate AMPK and have beneﬁcial
effects on these metabolic diseases. Herein, we set up a
high-throughput screening assay based on m and dis-
covered a small molecule C1 as a novel modulator of
mitochondrial function.
C1 treatment caused depolarization of mi nL 6m y o -
tubes in a relatively mild fashion, and a consequence of
this was activation of AMPK and improvements in meta-
bolic parameters both in vitro and in vivo. In principle,
several factors may lead to a drop in m, including
inhibition of mitochondrial respiration, induction of pro-
ton leakage (uncoupling), or opening of the mitochondrial
permeability transition pore. Mitochondrial permeability
transition pore opening is tightly correlated with initiation
of apoptosis (34), and we excluded this pathway, since we
observed no induction of markers of apoptosis after C1
treatment (data not shown). We also ruled out C1 acting
directly as an uncoupling agent, as it did not accelerate
respiration rate in isolated mitochondria, as typical uncou-
pling agents do (35). Similarly, uncoupling agents have
been shown to induce cell death (36), and we observed no
obvious toxicity on viability of a range of different cell
types (L6, Hela, A549, and PC12), even at high doses of C1
(data not shown). Collectively, our results suggested that
the likely mode of action of C1 to decrease m was
through inhibition of mitochondrial respiration.
Several antidiabetic agents, such as troglitazone, rosigli-
tazone, metformin, and berberine, have been shown to
inhibit mitochondrial respiratory complex I (10–14,37).
With our assay system, we conﬁrmed that these agents, as
expected, caused a decrease in m. Given that the effect
DMSO 10  20  40 10 µM CCCP
0
1
2
3
5
6
7
10
20
30
AC
DF
*
*
**
*
C1 (µM)
C1 (µM)
C1 (µM)
A
M
P
/
A
T
P
 
r
a
t
i
o
(
f
o
l
d
 
o
f
 
D
M
S
O
 
g
r
o
u
p
)
DMSO
10 min
20 min
30 min
60 min 0
1
2
3
4
5
6
7
*
* **
A
M
P
/
A
T
P
 
r
a
t
i
o
(
f
o
l
d
 
o
f
 
D
M
S
O
 
g
r
o
u
p
)
0 10 20 40 60
0
10
20
30
40
50
60
70
80
90
*
n
m
o
l
 
O
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
DMSO
20 µM C1
20 µM C1
50 µM Troglitazone 0
50
100
150
200
250
1 hr
4 hr
* *
* *
* *
* *
##
##
L
a
c
t
a
t
e
 
c
o
n
t
e
n
t
 
(
%
 
o
f
 
D
M
S
O
 
g
r
o
u
p
)
DMSO
2 mM Metformin 0
20
40
60
80
100
120
140
1 hr
4 hr * * * * * **
##
L
a
c
t
a
t
e
 
c
o
n
t
e
n
t
 
(
%
 
o
f
 
D
M
S
O
 
g
r
o
u
p
)
0 
200 
400 
600 
800 
1000 
1200 
1400 
0 5 10 20 0 5 10 20
n
m
o
l
 
O
/
m
i
n
/
m
g
 
p
r
o
t
e
i
n
 
Glutamate  Succinate 
E
B
FIG. 4. Effects of C1 on AMP-to-ATP ratio and respiration. Cellular ATP and AMP content were measured by HPLC as mentioned in RESEARCH
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B.-Y. QIU AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 261of C1 on m was of a comparable magnitude to the above
compounds, it seemed possible that C1 might act via a
similar mechanism. C1 dose-dependently inhibited respi-
ration in L6 myotubes, and this lead to an increase in the
AMP-to-ATP ratio. However, to our surprise, when we
examined isolated mitochondria, C1 did not affect ADP-
stimulated respiration with either glutamate or succinate
as the substrate. Therefore, C1 does not appear to inhibit
respiration via a direct effect on mitochondrial respiratory
complexes or the phosphorylation system (i.e., ATP syn-
thase and adenine nucleotide exchanger) (10). Another
important factor regulating mitochondrial respiration is a
constant supply of electron donors (e.g., NADH) (30).
There are several shuttle systems (e.g., malate-aspartate
shuttle, -glycerophosphate shuttle) that oxidize cytosolic
NADH and transfer the reducing equivalents to the mito-
chondrial respiratory chain (38). Inhibition of one of these
shuttles could lead to impairment in respiration in intact
cells, which would not be apparent using glutamate or
succinate as substrates in isolated mitochondria. For
example, the anti-inﬂammatory drug indomethacin, which
inhibits the -glycerophosphate shuttle, inhibits glucose
oxidation in intact kidney tubules, without affecting pyru-
vate oxidation in rat kidney mitochondria (39,40). Our
similar results for C1 suggest that it may also inhibit one of
these shuttle systems, and our ﬁnding of increased lactate
release support this, as a rise in cytosolic NADH/NAD

would favor the lactate dehydrogenase reaction (41).
A consequence of reduced mitochondrial respiration
and an elevated AMP-to-ATP ratio is activation of the
AMPK pathway, which induces a rapid shutdown of ana-
bolic processes and stimulation of catabolic processes to
try and overcome metabolic stress (26,28). Given its effect
on m it was not unexpected that we observed robust
stimulation of the AMPK pathway in L6 myotubes and
HepG2 cells with C1. The effects of C1 to stimulate glucose
uptake in L6 myotubes and to inhibit lipid synthesis in
HepG2 cells were also shown to be largely dependent on
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FIG. 5. Acute effect of C1 on respiratory exchange ratio (RER) and the AMPK pathway. For RER measurement, lean mice were placed in a
metabolic chamber at 9:00 A.M., and after2ho frest, C1 (50 mg/kg) or saline (vehicle) was administered by oral gavage. For acute experiment,
C57BL/6J lean mice were given either vehicle (0.9% NaCl) or C1 (20 mg/kg) or AICAR (400 mg/kg) by intraperitoneal injection. After 2-h
treatment, animals were killed, with liver freeze-clamped for the determination of phosphorylation of AMPK and ACC. A: Changes of RER
throughout the period of monitoring. B: Comparison of the average RER results before and after drug administration. C: The phosphorylation
state of liver AMPK and ACC. D and E: The ratio of phosphorylation level versus protein level of AMPK and ACC. **P < 0.01; *P < 0.05 compared
with vehicle (n  7–12).
TABLE 1
Chronic effects of C1 and metformin on metabolic parameters in mice
Plasma parameters db/db-Veh db/db-C1 db/db-Met Ln-Veh Ln-C1 Ln-Met
Food intake (g  day
1  mouse
1) 4.41  0.09 4.39  0.07 4.04  0.09 2.94  0.04 2.88  0.15 2.89  0.05
Body weight gain (g) 4.5  0.51 5.05  0.40 4.32  0.27 3.00  0.77 2.51  0.47 1.8  0.21
Fasting blood glucose (mmol/l) 21.9  1.9 17.3  1.5* 17.0  2.9* 10.7  0.5 11.2  0.5 10.0  0.6
Random-fed blood glucose (mmol/l) 20.3  1.8 11.8  0.7* 16.3  1.8* 11.0  0.3 12.3  0.6* 10.8  0.6
Plasma insulin (ng/ml) 8.06  1.37 10.99  2.09 8.29  1.13 0.48  0.03 0.43  0.03 0.48  0.03
Plasma NEFA (mEq/l) 1.18  0.09 0.96  0.05* 1.12  0.16 0.72  0.05 0.80  0.07 0.83  0.07
Plasma triglyceride (mmol/l) 0.85  0.03 0.82  0.04 0.91  0.18 0.66  0.06 0.63  0.05 0.67  0.03
Data are means  SE (n 
 7–10). Daily food consumption and body weight gain were measured during the study. Blood samples from mice
were collected after oral administration of vehicle (Veh) (0.5% methylcellulose) or C1 (50 mg  kg
1  day
1) or metformin (Met) (250 mg 
kg
1  day
1) for 4 weeks. *P 	 0.05 vs. vehicle.
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treatment with the AMPK inhibitor compound C. In fact,
the ability of AMPK to overcome a mild metabolic stress
represents an important protective mechanism, and it has
been shown that other agents that mildly inhibit or uncou-
ple mitochondria also increase glucose transport and
inhibit lipid synthesis (8,28,42,43).
Based on our in vitro ﬁndings, we sought to test the
effect of C1 in vivo. Pharmacokinetic studies in rats
showed favorable bioavailability of C1 (43%) and plasma
concentrations in the range that depolarized m and
activated AMPK in vitro (supplementary Fig. 1 in the online
appendix, available at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-0223/DC1). Initially, we administered
a single dose of C1 to mice, and while this did not
signiﬁcantly affect whole-body energy expenditure, we did
observe a reduction in the respiratory exchange ratio,
suggesting a switch to whole-body fatty acid oxidation.
These ﬁndings of elevated fat utilization are consistent
with activation of the AMPK pathway (26), which we
observed in the liver of lean animals dosed with C1. We
next assessed the chronic effects of 4 weeks of treatment
of C1 in db/db mice and lean mice. Neither C1 nor the
antidiabetic drug metformin had any major effect in lean
mice. In db/db mice, C1 improved glucose homeostasis to
a degree similar to that of metformin, as evidenced by the
reduction in blood glucose levels and improved glucose
tolerance. C1 also decreased plasma NEFA levels, which is
potentially a consequence of the enhanced whole-body fat
utilization we observed. Liver gluconeogenesis is a critical
component of glucose homeostasis, and we observed a
dose-dependent reduction in glucose output from primary
hepatocytes and a downregulation of hepatic PEPCK and
G6Pase expression by C1 in db/db mice. Interestingly, the
expression of G6Pase, but not PEPCK, was signiﬁcantly
upregulated by C1 treatment in lean animals. A number of
studies have reported that AMPK activators decrease
gluconeogenic gene expression (44,45); however, similar
to our ﬁndings, a recent study showed that AICAR treat-
ment of ob/ob mice potently upregulated the expression of
G6Pase in liver, while at the same time reducing the
expression of PEPCK (44). The reason for the disparity in
ﬁndings regarding AMPK activators and G6Pase expres-
sion is unclear at present.
Overall, we propose a scheme whereby C1 causes mild
inhibition of mitochondrial respiration, through a mecha-
nism distinct from TZDs, metformin, or berberine, ulti-
mately leading to activation of AMPK, with beneﬁcial
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FIG. 6. Chronic effects of C1 on glucose tolerance, gluconeogenic gene expression in mice, and
glucose output in primary hepatocytes. Eight-week-old lean mice or db/db mice were gavaged
with vehicle (0.5% methylcellulose) or C1 (50 mg  kg
1  day
1) or metformin (250 mg  kg
1 
day
1). A–D: Blood glucose levels after an intraperitoneal glucose load (2 g/kg) performed after
4 weeks of treatment in lean mice or db/db mice (n  7–9). Areas under the curve represented
as an indicator of glucose clearance. E, vehicle; , C1; , metformin; dotted line represents
lean mice group; solid line represents db/db mice group. *P < 0.05 compared with vehicle of
db/db mice (db/db-Veh). E and F: Effects on gluconeogenic gene expression in liver in lean mice
or db/db mice (n  7–9). **P < 0.01 compared with vehicle of lean mice (lean-Veh); ##P < 0.01
compared with vehicle of db/db mice (db/db-Veh). G: Effects on glucose output in primary
hepatocytes (n  3). *P < 0.05; **P < 0.01 compared with DMSO group.
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results with C1 and the fact that many prominent antidia-
betic compounds are known to inhibit mitochondrial
function, there are several potential concerns regarding
the use of compounds that target mitochondria. For ex-
ample, in addition to their role in energy production,
mitochondria play an important role in apoptotic signaling
and calcium regulation (46,47), and disruption of these
pathways may compromise cellular homeostasis. Further-
more, inhibiting ATP production in certain cells (e.g.,
pancreatic -cells) will have deleterious functional conse-
quences, as these cells rely on ATP as a key signaling
intermediate (30). We did not observe any obvious cyto-
toxic effects of C1 in our cell and animal studies, and the
only potentially negative ﬁnding was an increase in lactate
production in our cell studies. Lactic acidosis is an unde-
sirable side effect of metformin, and further studies are
required to determine if increased lactate levels occur in
vivo in response to all compounds that inhibit mitochon-
drial function, and whether this outweighs their beneﬁcial
effects on metabolism through AMPK activation.
In summary, we have used a screen for m to identify
a novel small molecule C1 that activates the AMPK path-
way and exerts beneﬁcial metabolic effects in vitro and in
vivo related to metabolic syndrome. Unlike other antidia-
betic agents that also work through the AMPK pathway,
C1 does not appear to directly affect mitochondrial com-
plex I, but indirectly inhibits mitochondrial function, po-
tentially through impairing the supply of electron donors.
Our ﬁndings therefore suggest that high-throughput
screening for compounds that mildly perturb mitochon-
drial function is a promising approach to discover novel
therapeutics for the treatment of type 2 diabetes and other
related metabolic diseases.
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